© 2021 Journal of Pharmacy & Pharmacognosy Research, 9 (3), 251-260, 2021
ISSN 0719-4250
http://jppres.com/jppres
Original Article
Ameliorative effect of Ruzu herbal bitters on high-fat diet induced
non-alcoholic fatty liver disease in Wistar rats
[Efecto mejorador de los amargos de hierbas de Ruzu en la enfermedad del hígado graso no alcohólico inducida por una dieta
alta en grasas en ratas Wistar]
Olubanke O. Ogunlana1,*, Babatunde O. Adetuyi2, Tobi S. Adekunbi1, Bose E. Adegboye1, Franklyn N. Iheagwam1; Oluseyi
E. Ogunlana3
1Department
of Biochemistry, College of Science and Technology, Covenant University, Ota, Ogun state, Nigeria.
of Natural Sciences, Precious Cornerstone University, Ibadan, Oyo state, Nigeria.
3Department of Biological Sciences, Crawford University, Igbesa, Ogun state, Nigeria.
*E-mail: banke.ogunlana@covenantuniversity.edu.ng
2Department
Abstract
Resumen
Context: One of the world's most widespread and frequent liver diseases
is the non-alcoholic fatty liver disease (NAFLD).
Contexto: Una de las enfermedades hepáticas más extendidas y
frecuentes del mundo es la enfermedad del hígado graso no alcohólico
(NAFLD).
Aims: To evaluate the preventives activities of Ruzu herbal bitters
(RHB), which is an anti-obesity therapeutic concoction used widely in
Nigeria on high–fat diet (HFD) induced NAFLD in albino Wistar rats.
Methods: A total number of twenty-five rats were isolated and divided
equally into five groups. Group 1, the normal control group was placed
on normal rat diet and normal saline (1 mL/kg body weight daily) for
twelve weeks. The remaining four groups 2-5 were placed on HFD for
twelve weeks; adding to the following treatment schedules by oral
gavage: group 2 received pioglitazone 4 mg/kg daily, group 3 received
RHB 0.6 mL/kg daily, group 4 received normal saline 1 mL/kg daily
and group 5 received fenofibrate 10 mg/kg daily (s.c). The animals were
sacrificed and biochemical markers of liver function, lipid profile,
glycemic index, and histopathological assessment of the liver of the rats
were determined.
Results: Rat treated with RHB and other treated groups significantly
(p<0.05) reduced the liver index, fasting blood glucose, and activities
and concentrations of liver function enzymes and molecules when
compared to untreated NAFLD group. Scoring of hepatic steatosis also
showed the ameliorative role of the treatment on NAFLD.
Conclusions: This study reveals that RHB and other treatment options
assessed could prevent HFD–induced NAFLD and could be explored as
another therapeutic approach to fenofibrate and pioglitazone in NAFLD
management.
Objetivos: Evaluar las actividades preventivas de los amargos de hierbas
Ruzu (RHB), que es un brebaje terapéutico contra la obesidad utilizado
ampliamente en Nigeria en la NAFLD inducida por una dieta alta en
grasas (HFD) en ratas Wistar albinas.
Métodos: Se aisló un total de veinticinco ratas y se dividió por igual en
cinco grupos. Grupo 1, el grupo de control normal recibió una dieta
normal para ratas y solución salina normal (1 mL/kg de peso corporal al
día) durante doce semanas. Los cuatro grupos restantes 2-5 se colocaron
en HFD durante doce semanas; añadiendo a los siguientes programas de
tratamiento por sonda oral: el grupo 2 recibió 4 mg/kg de pioglitazona
al día, el grupo 3 recibió 0,6 mL/kg de RHB al día, el grupo 4 recibió 1
mL/kg de solución salina normal al día y el grupo 5 recibió 10 mg/kg
de fenofibrato al día (s.c.). Los animales fueron sacrificados y se
determinaron marcadores bioquímicos de función hepática, perfil
lipídico, índice glucémico y evaluación histopatológica del hígado de las
ratas.
Resultados: Las ratas tratadas con RHB y otros grupos tratados redujeron
significativamente (p<0,05) el índice hepático, la glucosa en sangre en
ayunas y las actividades y concentraciones de las enzimas y moléculas
de la función hepática en comparación con el grupo NAFLD no tratado.
La puntuación de la esteatosis hepática también mostró el papel
mejorador del tratamiento en NAFLD.
Conclusiones: Este estudio revela que la RHB y otras opciones de
tratamiento evaluadas podrían prevenir la NAFLD inducida por HFD y
podrían explorarse como otro enfoque terapéutico para el fenofibrato y
la pioglitazona en el manejo de la NAFLD.
Keywords: high–fat diet; liver; non-alcoholic fatty liver disease;
pioglitazone; Ruzu herbal bitters.
Palabras Clave: amargos de hierbas de Ruzu; dieta rica en grasas;
enfermedad del hígado graso no alcohólico; hígado; pioglitazona.
ARTICLE INFO
Received: May 26, 2020.
Received in revised form: August 14, 2020.
Accepted: August 15, 2020.
Available Online: December 9, 2020.
_____________________________________
Ogunlana et al.
INTRODUCTION
The chronic liver disease, non-alcoholic fatty
liver disease (NAFLD) is one of the major causes
of liver diseases in childhood, adolescence, and
adults (Zaitone et al., 2011). NAFLD is a prevalent
type of fatty liver malady, developed not as a result of excessive alcohol intake and is associated
with insulin resistance and obesity (Pastori et al.,
2015). NAFLD is characterized by hepatic steatosis
(HS) ≥5%, when there is non-appearance of some
other competing liver diseases cause, for example
use of medications, hemochromatosis, chronic viral hepatitis, Wilson's disease, autoimmune hepatitis, and substantial alcohol intake (Mishra and
Younossi, 2012). The genesis of NAFLD shows as
accumulation of massive droplets in the liver cells,
which eventually stimulates the induction of type
2 diabetes, obesity, hyperlipidaemia, resistance of
insulin and another metabolic syndrome (Birkenfeld and Shulman, 2014). In NAFLD, triacylglycerides accumulates in the liver as HS because of an
imbalance between storage and removal of lipids
(Taylor, 2008). This eventually progresses into steatohepatitis, then to fibrosis and cirrhosis (Dowman et al., 2010). Patients with NAFLD with simple steatosis rarely transform to other forms of
liver diseases, however about 20% of individuals
with non-alcoholic steatohepatitis (NASH) advances to cirrhosis and fibrosis over a period of 15
years (Angulo, 2010). The pathogenesis underlying
steatosis and its progression to NASH is proposed
as a two-hit hypothesis (Day and James, 1998).
According to this hypothesis, there is firstly the
induction of liver fat accumulation and then insulin resistance, which eventually prompts the progression of steatosis to non-alcoholic steatohepatitis.
Globally, the prevalence of NAFLD has been
directly proportional to the prevalence of obesity,
diabetes, and metabolic syndrome (MS) (Alisi et
al., 2012). It has been estimated that the burden of
NAFLD, by the year 2021 will increase to about
60% (Akala and El-Saharty, 2006). It must be noted
that the major cause of morbidity and mortality in
NAFLD is cardiovascular disorders. It is considhttp://jppres.com/jppres
Effect of Ruzu herbal bitters on high-fat diet in rats
ered as the most common liver disease in Western
societies and affects up to 35% of the population in
several countries (Clark, 2006). Notably, 1-5% of
patients with simple steatosis can eventually develop actual cirrhosis; and 10-15% of patients with
NASH can progress to cirrhosis and eventually to
hepatocellular carcinoma (Ascha et al., 2010).
Globally, there are at least 400 million obese
adults in low-, middle- and high-income countries
(Ogden et al., 2006). Previous studies have estimated that 75% of those with obesity have NAFLD
(Clark, 2006). The prevalence of NAFLD in the
United States is reported to be between 10% and
30%, with similar rates reported from Europe
(23%), South America (31%), Middle East (32%)
and Asia (27%). The diagnosis, treatment, and
management of NAFLD are a major problem in
Africa. However, in Nigeria, NAFLD prevalence is
between 9.5–16.7% in individuals with diabetes
and 1.2–4.5% in individuals without diabetes
(Onyekwere et al., 2011). At present, there is lack
of consensus on the management of NAFLD, and
consequently no drug is currently indicated for the
treatment of NAFLD. However, since NAFLD is a
multifactorial disease, approaches that combine
reducing visceral adiposity, insulin resistance and
hyperinsulinemia among others have been indicated as possible way out. Lifestyle intervention
(diet, exercise) represents the mainstay of treatment (Rajwal and McClean, 2017).
Ruzu herbal bitters (RHB) is a poly-herbal mixture prepared in Nigeria and widely used as an
anti-obesity concoction. It has unverified claims
for the management of obesity, diabetes, hypertension, arthritis and infertility, liver toning capacity,
among others. It is an aqueous preparation of Curculigo pilosa root (40%), Uvaria chamae stem (20%)
and Citrullus colocynthis bark (40%). The phytochemical analysis of RHB showed that the product
is rich in saponins (0.77 mg/mL), alkaloids (0.76
mg/mL), flavonoids (0.73 mM), and cardiac glycosides (0.32 mM), while phenols (0.09 mg/mL),
steroids (0.09 mg/mL) and tannins (0.01 mg/mL)
are least amongst the phytochemicals analyzed
(Obasi et al., 2020). C. pilosa has been used tradiJ Pharm Pharmacogn Res (2021) 9(3): 252
Ogunlana et al.
tionally to treat impotence, arthritis, gastrointestinal and heart diseases (Nie et al., 2013). A thorough examination of the phytochemical screening
of C. pilosa shows that it possesses antioxidant,
neuroprotective and hepatoprotective activity (Nie
et al., 2013). U. chamae has been reported for treating severe abdominal pains, diarrhea, sickle cell
anemia, cough, urinary tract, and cerebral infections as well as possesses hepatoprotective activity
(Oluremi et al., 2010). C. colocynthis plant is widely
recognized for its wide range of medicinal applications and uses, as well as its pharmaceuticals and
nutraceutical potentials (Aldhahi and Hamdy,
2003). The saponin extract of C. colocynthis fruits at
different doses lowers the fasting blood glucose
levels in alloxan diabetic rabbits significantly
when administered orally (Abdel-Hassan et al.,
2000). The antilipidemic, antioxidant and hepatoprotective activity of RHB has been attributed to
the presence of U. Chamae and C. Colocynthis present in it (Ogunlana et al., 2018). Despite these
studies, there is a paucity of information on the
effect of RHB in the treatment/prevention of
NAFLD. This study is therefore aimed at evaluating the protective activities of RHB in an experimental NAFLD animal model induced by high fat
diet.
MATERIAL AND METHODS
Chemicals and reagents
Ethylenediaminetetraacetic acid (EDTA), 4-(2hydroxyethyl)-1-piperazine ethanesulfonic acid
(HEPES),
5,5'-dithiobis(2-nitrobenzoic
acid)
(DTNB), 1-chloro-2,4-dinitrobenzene (CDNB), thiobarbituric acid (TBA), pyrogallol, trichloro acetic
acid (TCA), sodium hydroxide, hydrochloric acid
were purchased from Sigma-Aldrich. Ruzu herbal
bitters (RHB) was obtained from A2W Global Ltd.,
Lagos, with National Agency for Food and Drug
Administration and Control (NAFDAC) Registration Number A7-1102L. Pioglitazone hydrochloride (>99% purity) was obtained from Tokyo
Chemical Industry, Development Co. Ltd., Shanghai. Fenofibrate and cholesterol were also obtained
from Fisher Scientific. All other chemicals and reagents used in the study were of analytical grade.
http://jppres.com/jppres
Effect of Ruzu herbal bitters on high-fat diet in rats
Experimental animals
Twenty-five Male albino rats of Wistar strain
weighing between 130-170 g were housed in a neat
and well-ventilated propylene cages and maintained under standardized laboratory conditions
(12 h light/dark cycle, 24°C) and provided free
access to normal and high-fat diet and drinking
water ad libitum. Animals were procured from Lagos State University Teaching Hospital Idi araba,
Lagos State, Nigeria. They were allowed to acclimatize for two weeks before commencement of
experiment. All experiments and protocols described in the present study were approved by the
Institutional Animal Ethics Committee, an arm of
the Covenant Health Research Ethics Committee
of the University with approval number
(CU/HREC/ATS06/19. The experimental procedures and animals care were performed in accordance with the “Guide for the care and use of laboratory animals” and “Committee for the purpose of
control and supervision on experimental animals”
(CPCSEA) in order to minimize pain and discomfort.
Experimental diet
The diets used in this study were of two types,
the normal rat chow and high-fat diet (HFD),
which were compounded and manufactured from
Graceline Feed Ltd., Ota, Ogun State. The formulations were as described in Ogunlana et al. (2020).
Experimental design
Animal model
The experiment was carried out using twentyfive albino male Wistar rats that were housed at
constant temperature with exposure to 12 h of
dark/light condition and free access to food and
water ad libitum. Animals were allowed to acclimatize for two weeks before the commencement of
the experiment. The animals were weighed before
the commencement of treatment and weekly
throughout the duration of study. Thereafter, the
animals were randomly grouped into five of five
animals in each group. Table 1 shows experimental design and treatments of animals.
J Pharm Pharmacogn Res (2021) 9(3): 253
Ogunlana et al.
Effect of Ruzu herbal bitters on high-fat diet in rats
Table 1. Experimental design and treatment of animals.
Group
Name
Treatment of animals
1
Normal control
(Normal)
Fed standard rat diet and given normal saline (1 mL/kg body weight (BW)/day)
by gastric intubation for twelve weeks
2
Pioglitazone (PIO)
Fed high fat diet and given pioglitazone (4 mg/kg BW/day) by gastric
intubation for twelve weeks
3
Ruzu herbal
bitters (Ruzu)
Fed high fat diet and given Ruzu (0.6 mL/kg BW/day); an equivalent of the
prescribed adult human dosage) by gastric intubation for twelve weeks
4
Non-alcoholic
fatty liver disease
(NAFLD)
Fed high fat diet and given normal saline (1 mL/kg BW/day) by gastric
intubation for twelve weeks
5
Fenofibrate
(FENO)
Fed high fat diet and given fenofibrate (10 mg/kg BW/day) by sub-cutaneous
injection for twelve weeks
The physical appearance and daily activities of
the rats, such as eating patterns and signs of abnormalities, were observed and recorded. Body
weight of the animals were measured weekly
throughout the duration of the experiment. At the
end of the twelve weeks, fasting blood glucose
evaluation was carried out using standard diagnostic kit (Accu-Check Diagnostics, England),
thereafter, the animals were sacrificed using mild
anesthesia (sodium pentobarbital 50 mg/kg (2.5
mL/kg, i.p.) and blood collected from the heart
using heparinized syringes.
Sample preparation
Plasma was obtained from whole blood collected in heparinized tube by centrifugation (Thermo
Scientific Legend Micro 21 centrifuge, Thermo
Fisher Scientific, Waltham, Massachusetts, U.S.A)
at 3000 rpm for 10 min. Liver was excised, rinsing
with normal saline and homogenized in ice-cold
homogenization buffer (0.25 M sucrose, 10 mM
Tris-HCL, 1 mM EDTA and 10 mM Hepes-NaOH
at pH 7.4) using a Teflon pestle homogenizer
(Thomas Pestle tissue homogenizer, Thomas Scientific, Swedesboro, New Jersey, U.S.A). The homogenate was centrifuged at 12 000 g for 10 min in 4°C
temperature. The supernatant was collected and
frozen at 20°C for enzymatic assays. A portion of
liver was stored in 10% neutral buffered formalin
for histology.
http://jppres.com/jppres
Determination of liver function parameters
Liver function biomarkers including alanine
aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), triglycerides, total bilirubin, direct bilirubin, indirect bilirubin, total protein, albumin, and cholesterol were
carried out according to manufacturer’s instructions (Randox Laboratories, UK). Readings were
taken by spectroscopic methods of analysis using
UV/Visible spectrophotometer (Thermo Fisher
Scientific, Genesys, USA).
Histological examination
Neutral buffered formalin (10%) fixed liver tissues were embedded in paraffin wax, sectioned,
stained using hematoxylin and eosin (H&E),
viewed under the microscope, and analyzed by a
pathologist according to the method as described
by Ogunlana et al. (2013). Briefly, fixed liver tissues were dehydrated and cleared in methanol
and xylene, respectively. Wax infiltration and embedding were carried out in rotary microtome.
Thereafter, tissues sections (5 µm) were made,
mounted on glass slides, and stained with stained
with H&E. The slides were analyzed under the
light microscope (Olympus BX63 with a DP72
camera, Olympus Corporation, Tokyo, Japan) at
400× and sections were observed for vascular congestion and inflammation and scored.
J Pharm Pharmacogn Res (2021) 9(3): 254
Ogunlana et al.
Statistical analysis
Data were analyzed using statistical package
for social science (SPSS version 23). The analyzed
data was documented as mean ± SEM of five replicates in each group. Analysis of Variance
(ANOVA) will be carried out to test for the level of
homogeneity at p˂0.05 among the groups. Duncan’s Multiple Range Test (MRT) will be used to
separate the heterogeneous group.
RESULTS
Liver index
Fig. 1D shows the liver index of rats in all the
groups. There was significant (p˂0.05) increase in
the relative liver weight of all the groups in comparison with normal control.
Fasting blood glucose
Fig. 1A shows the fasting blood glucose of the
experimental on the last day of the experiment.
NAFLD animals had significantly (p<0.05) increased fasting blood glucose levels in comparison
to normal control, pioglitazone (PIO), Ruzu herbal
bitters (Ruzu), and fenofibrate (FENO). However,
the significant decrease in the blood glucose levels
of rat treated with Ruzu was not comparable to
animals treated with pioglitazone and fenofibrate.
Biochemical markers of liver function
biomarkers in the blood
The concentrations of albumin (ALB) (Fig 1K),
total cholesterol (TC) (Fig. 1E) and triglycerides
(TRIG) (Fig. 1F), total bilirubin (Fig. 1H), direct
and indirect bilirubin (Fig. 1I-J) were significantly
reduced in treatment groups in comparison to
negative control, NAFLD group. In addition, the
activities of aspartate aminotransferase (AST) (Fig.
1B), alanine aminotransferase (ALT) (Fig. 1C) and
alkaline phosphatase (ALP) (Fig. 1G) were significantly (p˂0.05) reduced in normal control and other treatment groups when compared to the
NAFLD group (Fig. 1).
http://jppres.com/jppres
Effect of Ruzu herbal bitters on high-fat diet in rats
Histological architecture and scoring of hepatic
steatosis
Fig. 2 illustrates the histological architecture
and grading of the liver steatosis of the liver of the
rat. Score of hepatic steatosis was used to assess
the level of liver damage or its improvement. Level of hepatic steatosis was scored from 0, 1 to 5,
reflecting no steatosis (0), mild steatosis (1), mild
to moderate (2), moderate (3), moderate to severe
(4) and severe steatosis and cellular infiltration (5).
Normal control group and rats treated with fenofibrate had no visible steatosis and scored 0, while
rats treated with pioglitazone and Ruzu had mild
to moderate and moderate level of hepatic steatosis, respectively. However, the NAFLD rats has
severely diffused hepatic steatosis characteristics
of the disease state.
DISCUSSION
The general unverified use of non-alcoholic
Ruzu herbal bitters in Nigeria, West Africa and
elsewhere for a number of health-related issues,
which involves detoxification of the liver among
other reasons, has motivated pharmacological
studies of the decoction. HFD induction of NAFLD
has been used to study the ameliorative roles of
medicinal plants and plant phytochemicals in laboratory animals. High fat diet (HFD) feeding in
rats for twelve weeks in the present study induced
severe steatosis, portal inflammation, elevated
glycaemic index, blood lipids and liver function
enzymes, which are characteristics of NAFLD. The
typical histopathological non-alcoholic steatohepatitis lesions observed in this study is consistent
with the study of Zaitone et al. (2011).
A significant liver index, as observed in the
NAFLD group demonstrates a substantial weight
gain as reported previously (Elshazly, 2015; Ogunlana et al., 2018; 2020). Weight gain in experimental animal may result from lipid bioaccumulation in the hepatocytes and blood circulation. The
marked increase in fasting blood sugar (FBS) observed in the NAFLD group may predispose the
J Pharm Pharmacogn Res (2021) 9(3): 255
Ogunlana et al.
Effect of Ruzu herbal bitters on high-fat diet in rats
test animals to prediabetes state. The two major
risk factors of NAFLD are dyslipidemia and insu-
lin resistance (Fernandez–Miranda et al., 2008).
A
B
C
D
E
F
G
H
I
J
K
Figure 1. Biochemical markers of
liver function.
Data are presented as mean ± SEM, (n =
5); ap˂0.05 shows significant difference
when compared to Normal Control.
bp˂0.05 shows significant difference
when compared to NAFLD group.
NAFLD: non-alcoholic fatty liver disease, PIO: pioglitazone (4 mg/kg body
weight), RUZU: Ruzu herbal bitters (0.6
mg/kg body weight), FENO: fenofibrate (10 mg/kg body weight).
http://jppres.com/jppres
J Pharm Pharmacogn Res (2021) 9(3): 256
Ogunlana et al.
Effect of Ruzu herbal bitters on high-fat diet in rats
A
B
C
D
E
Figure 2. Histological architecture of the liver.
(A) NAFLD group: Score: 5 – severe diffused steatosis seen
(arrows pointing to severely diffuse steatosis with
periportal cellular infiltration).
(B) Fenofibrate group: Score: 0 – steatosis not seen.
(C) Ruzu group: Score: 3 – moderate diffused steatosis seen
(arrow pointing to moderately diffused steatosis with
portal congestion/infiltration).
(D) Normal group: Score: 0 – steatosis not seen.
(E) Pioglitazone: Score: 1 – mild steatosis seen (arrow
pointing to very mild steatosis with mild congestion).
The increase in FBS is ameliorated by treatment
with pioglitazone, Ruzu and fenofibrate. The insulin enhancing activity of Ruzu, pioglitazone and
http://jppres.com/jppres
fenofibrate in reducing FBS and consequently
causing a reduction in plasma insulin has been
reported previously. Ruzu and others may play a
J Pharm Pharmacogn Res (2021) 9(3): 257
Ogunlana et al.
protective role of the endocrine system by improving insulin sensitivity of the tissues to glucose uptake and thereby, improving lipid and glucose
metabolism (Fernandez–Miranda et al., 2008; Kale
et al., 2018; Ogunlana et al. 2018).
The increase in the levels of plasma conjugated
and unconjugated bilirubin as a result of diet induced NAFLD was significantly reduced in all the
treatment groups. Unconjugated hyperbilirubinemia can result from increased production,
impaired conjugation, or impaired hepatic uptake
of bilirubin, a bile pigment produced from the
degradation of hemoglobin. Hepatocellular disease such as NAFLD can cause a mixture of plasma unconjugated and conjugated hyperbilirubinemia due to both impaired bilirubin conjugation and canalicular excretion. Defects in conjugated bilirubin excretion may cause isolated conjugated hyperbilirubinemia without cholestasis
(Harb and Thomas, 2007). The hepatocellular disease characterized by conjugated and unconjugated hyperbilirunemia was reversed by hepatoprotective activity of Ruzu, pioglitazone and fenofibrate. This report was in agreement with previous report (Ogunlana et al., 2018).
In addition, the significant elevation in the total
plasma cholesterol and triglycerides concentrations observed in NAFLD group were reversed in
treatment groups. This observation was in consonance with the findings of other researchers
(Gomathy et al., 1989; Šeböková et al., 2002; Xu et
al., 2006; Yalniz et al., 2007; Guo et al., 2012; Ogunlana et al., 2018). C. colocynthis, a major constituent
in Ruzu, induced a dose dependent suppression of
the intracellular triglyceride accumulation during
adipogenesis. The downregulation and inhibition
of main transcription factors of adipogenesis,
which include CCAAT/enhancer binding protein
α (C/EBPα), peroxisome proliferator activated
receptor γ (PPARγ), and sterol regulatory elementbinding protein 1c (SREBP-1c) were reported
(Jemai et al., 2020). Equally, the expression of
PPARα, a transcription factor for lipid catabolism
and its associated genes, which include CPT1A,
CPT2 and CYP4b10 were decreased in NAFLD
http://jppres.com/jppres
Effect of Ruzu herbal bitters on high-fat diet in rats
(Wahlang et al., 2014). Hypolipidemia activity may
result from the decrease in the absorption of intestinal cholesterol by plant phytochemicals (Chan
and Tang, 1995). Hence, Ruzu may play a significant antilipidemic role in the treatment of obesity
owing to its powerful effects on fat, by the activation of lipid oxidation genes, inactivation of adipogenesis genes and/or by reducing the intestinal
absorption of cholesterol. Hence, promoting hepatic lipid catabolism and protective roles against
steatosis.
The reversal in the marked elevation observed
in the activities of AST and ALT in NAFLD groups
were demonstrated in all the treatment groups.
This is in agreement with previous reported works
(Pan et al., 2006; Yalniz et al., 2007; Fernandez–
Miranda et al., 2008; Hamed et al., 2017; Ogunlana
et al., 2018). The liver function parameters are biomarkers for the assessment of the functionality
and integrity of the hepatocytes. The hepatoprotective activities of Ruzu may be due to the presence of plant phytochemicals in its constituents.
The hepatoprotective activity of C. colocynthis has
been documented in animals (Arjaibi et al., 2017;
Sari et al., 2019). This activity has been linked to
the presence of cucurbitacins, a major phytochemical and others in C. colocynthis. Antioxidant, free
radical scavenging, and anti-inflammatory activities of the phytoconstituents in C. colocynthis and
Ruzu have been reported (Tannin-Spitz et al., 2007;
Arjaibi et al., 2017; Ogunlana et al., 2020). In the
current study, the histopathological findings of the
hepatocytes further revealed the protective and
hypolipidemic effects of Ruzu and other treatment
options.
CONCLUSIONS
The results of this study demonstrate that Ruzu
herbal bitters possesses hepatoprotective, hypoglycemic and hypolipidemic activities, hence, was
able to comparatively with standard drugs ameliorates HFD induced NAFLD in Wistar rats. Thus,
Ruzu herbal bitters may be considered as an alternative therapy to pioglitazone and fenofibrate in
the clinical management of NAFLD.
J Pharm Pharmacogn Res (2021) 9(3): 258
Ogunlana et al.
CONFLICT OF INTEREST
The authors declare that they have no conflict of interest
with respect to the research, authorship, or publication of this
article.
ACKNOWLEDGMENTS
The research was partly supported by Covenant
University Institutional grant (CU/CRD/VC/13.11.22/01) to
Ogunlana O.O (Department of Biochemistry, Covenant
University, Nigeria). Appreciation to Dr. Aino O.O. of the
Department of Veterinary Anatomy, University of Ibadan for
the histopathological scoring of the liver. The authors
acknowledge Covenant University Centre for Research,
Innovation and Discovery (CUCRID) for the payment of the
article charges.
REFERENCES
Abdel-Hassan IA, Abdel-Barry JA, Mohammeda ST (2000)
The hypoglycaemic and antihyperglycaemic effect of
Citrullus colocynthis fruit aqueous extract in normal and
alloxan diabetic rabbits. J Ethnopharmacol 71(1-2): 325–
330.
Akala FA, El-Saharty S (2006) Public-health challenges in the
Middle East and North Africa. Lancet 367(9515): 961–964.
Aldhahi W, Hamdy O (2003) Adipokines, inflammation, and
the endothelium in diabetes. Curr Diab Rep 3(4): 293–298.
Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V (2012)
Non-alcoholic fatty liver disease and metabolic syndrome
in adolescents: pathogenetic role of genetic background
and intrauterine environment. Ann Med 44(1): 29–40.
Angulo P (2010) Long‐term mortality in nonalcoholic fatty
liver disease: is liver histology of any prognostic
significance? J Hepatol 51(2): 373–375.
Arjaibi HM, Ahmed MS, Halaweish FT (2017) Mechanistic
investigation of hepato-protective potential for
cucurbitacins. Med Chem Res 26(7): 1567–1573.
Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein
AF, Zein NN (2010) The incidence and risk factors of
hepatocellular carcinoma in patients with nonalcoholic
steatohepatitis. J Hepatol 51(6): 1972–1978.
Birkenfeld AL, Shulman GI (2014) Nonalcoholic fatty liver
disease, hepatic insulin resistance, and type 2 diabetes. J
Hepatol 59(2): 713–723.
Chan TY, Tang PL (1995) Effect of melatonin on the
maintenance of cholesterol homeostasis in the rat. Endocr
Res 21(3): 681–696.
Effect of Ruzu herbal bitters on high-fat diet in rats
Dowman JK, Tomlinson JW, Newsome PN (2010)
Pathogenesis of non-alcoholic fatty liver disease. QJM-Int
J Med 103(2): 71–83.
Elshazly SM (2015) Ameliorative effect of nicorandil on high
fat diet induced non-alcoholic fatty liver disease in rats.
Eur J Pharmacol 748: 123–132.
Fernández-Miranda C, Pérez-Carreras M, Colina F, LópezAlonso G, Vargas C, Solís-Herruzo JA (2008) A pilot trial
of fenofibrate for the treatment of non-alcoholic fatty liver
disease. Digest Liver Dis 40(3): 200–205.
Gomathy R, Vijayalekshmi NR, Kurup PA (1989)
Hypolipidemic principle of the inflorescence stalk of
plantain (Musa sapientum). J Biosci 14(3): 301–309.
Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, Hou R, Qin Y
(2012) Meta-analysis of safety of the coadministration of
statin with fenofibrate in patients with combined
hyperlipidemia. Am J Cardiol 110(9): 1296–1301.
Hamed AM, El-Kharashi OA, Boctor SS, Abd-Elaziz LF (2017)
Potential involvement of PPAR α activation in
diminishing the hepatoprotective effect of fenofibrate in
NAFLD: accuracy of non-invasive panel in determining
the stage of liver fibrosis in rats. Biomed Pharmacother
85: 68–78.
Harb R, Thomas DW (2007) Conjugated hyperbilirubinemia:
screening and treatment in older infants and children.
Pediatr Rev 28(3): 83–91.
Jemai R, Drira R, Makni M, Fetoui H and Sakamoto K (2020)
Colocynth (Citrullus colocynthis) seed extracts attenuate
adipogenesis by down-regulating PPARγ/SREBP-1c and
C/EBPα in 3T3-L1 cells. Food Bioscience 33: 100491.
Kale OE, Akinpelu OB, Bakare AA, Yusuf FO, Gomba R,
Araka DC, Ogundare TO, Okolie AC, Adebawo O and
Odutola O (2018) Five traditional Nigerian polyherbal
remedies
protect
against
high
fructose
fed,
streptozotocin-induced type 2 diabetes in male Wistar
rats. BMC Complem Altern M 18(1): 160.
Mishra A, Younossi ZM (2012) Epidemiology and natural
history of non-alcoholic fatty liver disease. J Clin Exp
Hepatol 2(2): 135–144.
Nie Y, Dong X, He Y, Yuan T, Han T, Rahman K, Qin L,
Zhang Q (2013) Medicinal plants of genus Curculigo:
traditional
uses
and
a
phytochemical
and
ethnopharmacological review. J Ethnopharmacol 147(3):
547–563.
Obasi DC, Ogugua VN, Obasi JN, Okagu IU (2020)
Phytochemical, nutritional and anti-nutritional analyses
of Ruzu herbal bitters. IOSR J Pharm Biol Sci 15(1): 4–17.
Clark JM (2006) The epidemiology of nonalcoholic fatty liver
disease in adults. J Clin Gastroenterol 40: S5–S10.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ,
Flegal KM (2006) Prevalence of overweight and obesity in
the United States, 1999-2004. JAMA 295(13): 1549–1555.
Day CP, James OF (1998) Steatohepatitis: a tale of two “hits”?
Gastroenterology 114(4): 842–845.
Ogunlana OO, Ogunlana OE, Adekunbi TS, Adetuyi BO,
Adegboye BE, Iheagwam FN (2020) Anti-inflammatory
http://jppres.com/jppres
J Pharm Pharmacogn Res (2021) 9(3): 259
Ogunlana et al.
Effect of Ruzu herbal bitters on high-fat diet in rats
mechanism of Ruzu bitters on diet-induced nonalcoholic
fatty liver disease in male Wistar rats. Evid Based
Complementary Altern Med 2020: 5246725.
Ogunlana OO, Ogunlana OE, Ugochukwu SK, Adeyemi AO
(2018) Assessment of the ameliorative effect of Ruzu
herbal bitters on the biochemical and antioxidant
abnormalities induced by high fat diet in Wistar rats. Int J
Pharmacol 14(3): 329–341.
Ogunlana OO, Ogunlana OE, Adeneye AA, Udo-Chijioke
OAC, Dare-Olipede TI, Olagunju JA and Akindahunsi
AA (2013) Evaluation of the toxicological profile of the
leaves and young twigs of Caesalpinia bonduc (Linn) roxb.
Afr J Tradit Complement Altern Med 10(6): 504–512.
Oluremi BB, Osungunna MO, Omafuma OO (2010)
Comparative assessment of antibacterial activity of Uvaria
chamae parts. Afr J Microbiol Res 4(13): 1391–1394.
Onyekwere CA, Ogbera AO, Balogun BO (2011) Nonalcoholic fatty liver disease and the metabolic syndrome
in an urban hospital serving an African community. Ann
Hepatol 10(2): 119–124.
Pan M, Song YL, Xu JM, Gan HZ (2006) Melatonin ameliorates
nonalcoholic fatty liver induced by high‐fat diet in rats. J
Pineal Res 41(1): 79–84.
Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico
F (2015) The efficacy and safety of statins for the
treatment of non-alcoholic fatty liver disease. Digest Liver
Dis 47(1): 4–11.
Rajwal S, McClean P (2017) Non-alcoholic fatty liver disease.
Paediatr Child Health 27(12): 556–560.
of Citrullus colocynthis seeds oil in high-fat diets induced
obese rats. Phytothérapie 17(6): 310–320.
Šeböková E, Kürthy M, Mogyorosi T, Nagy K, Demcákova E,
Ukropec J, Koranyi L, Klimeš I (2002) Comparison of the
extrapancreatic action of BRX‐220 and pioglitazone in the
high‐fat diet‐induced insulin resistance. Ann N Y Acad
Sci 967(1): 424–430.
Tannin-Spitz T, Bergman M, Grossman S (2007) Cucurbitacin
glucosides: Antioxidant and free-radical scavenging
activities. Biochem Biophys Res Commun 364(1): 181–186.
Taylor R (2008) Pathogenesis of type 2 diabetes: tracing the
reverse route from cure to cause. Diabetologia 51(10):
1781–1789.
Wahlang B, Song M, Beier JI, Falkner KC, Al-Eryani L, Clair
HB, Prough RA, Osborne TS, Malarkey DE, States JC,
Cave MC (2014) Evaluation of Aroclor 1260 exposure in a
mouse model of diet-induced obesity and non-alcoholic
fatty liver disease. Toxicol Appl Pharm 279(3): 380–390.
Xu P, Zhang XG, Li YM, Yu CH, Xu L, Xu GY (2006) Research
on the protection effect of pioglitazone for non-alcoholic
fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B
7(8): 627–633.
Yalnız M, Bahçecioğlu İH, Kuzu N, Çelebi S, Ataseven H,
Üstündağ B, Özercan İH, Şahin K (2007) Amelioration of
steatohepatitis with pentoxifylline in a novel nonalcoholic
steatohepatitis model induced by high-fat diet. Digest Dis
Sci 52(9): 2380–2386.
Zaitone S, Hassan N, El-Orabi N, El-Awady ES (2011)
Pentoxifylline and melatonin in combination with
pioglitazone ameliorate experimental non-alcoholic fatty
liver disease. Eur J Pharmacol 662(1-3): 70–77.
Sari MC, Nemmiche S, Benmehdi H, Amrouche A, Hamadi
AL, Sari DC (2019) Hypolipidemic and antioxidant effects
_________________________________________________________________________________________________________
AUTHOR CONTRIBUTION:
Contribution
Ogunlana OO
Adetuyi BO
Adekunbi TS
Adegboye BE
Iheagwam FN
Ogunlana OE
Concepts or ideas
x
x
Design
x
x
Definition of intellectual content
x
Literature search
x
x
Experimental studies
x
x
x
Data acquisition
x
x
x
Data analysis
x
x
x
x
Statistical analysis
x
x
x
x
Manuscript preparation
x
x
x
Manuscript editing
x
x
x
x
x
x
Manuscript review
x
x
x
x
x
x
Citation Format: Ogunlana OO, Adetuyi BO, Adekunbi TS, Adegboye BE, Iheagwam FN, Ogunlana OE (2021) Ameliorative effect of Ruzu
herbal bitters on high-fat diet induced non-alcoholic fatty liver disease in Wistar rats. J Pharm Pharmacogn Res 9(3): 251–260.
http://jppres.com/jppres
J Pharm Pharmacogn Res (2021) 9(3): 260